CELU Celularity Inc.
Price Chart
Executive Summary
Celularity disclosed a Nasdaq late filing notice for its overdue Q1 2026 10-Q. The delayed filing triggers a 60-day cure period to submit a compliance plan, with a potential 180-day extension. For a $29M market cap company already trading on the Nasdaq Capital Market, this increases delisting risk and undermines investor confidence in timely financial reporting.
Actionable Insight
Short-term traders should expect downward pressure as delisting risk reprices the stock. Monitor for the compliance plan submission by July 28, 2026; failure to file by November 16, 2026 could result in suspension and eventual delisting. Positive resolution (timely filing) would likely reverse the bearish sentiment, but near-term catalysts are absent.
Key Facts
- Celularity received a Nasdaq notification on May 27, 2026 for failure to timely file its Q1 2026 10-Q (Rule 5250(c)(1)).
- The company has 60 days (until July 28, 2026) to submit a compliance plan; if accepted, it may receive up to 180 additional days (until November 16, 2026) to file.
- Nasdaq stated the notification has no immediate impact on CELU trading, which continues on the Nasdaq Capital Market.
- The company has a $29M market cap and a history of delayed filings, compounding execution risk.
- Cross-filing actuarial verdicts show press-activist + press-offering and press-8k + press-activist combos are amplifiers, suggesting elevated market reaction to Nasdaq-delinquency news in this context.
Financial Impact
No specific financial impact stated; late filing risk adds uncertainty and potentially elevates cost of capital or triggers debt/equity covenants. For a micro-cap, the delisting scare alone can pressure the stock.
Risk Factors
- Potential Nasdaq delisting if the 10-Q is not filed within the extension period; delisting would severely impair liquidity and equity value.
- The late filing may signal deeper accounting or operational issues; prior historical performance shows high volatility with -34.59% T+20 return on a neutral call, consistent with negative stock reactions to bad news on this name.
- Cross-filing scores suggest past high-impact events on this segment have symmetric downside (μ_l -35.5% at score=7), so bearish sentiment with score 6 is appropriate given the asymmetric risk.
- No quantitative financial data (revenue, EPS, cash) is provided in the release, making it impossible to assess underlying business health.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303835 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
14d ago
|
Press Release
| $1.07 $0.8720 | ▲ +18.50% | ▲ +15.75% | $0.7130 (+33.36%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $1.22 $1.04 | ▼ −14.75% | ▼ −15.84% | $0.7130 (−41.56%) |
|
Apr 17, 2026
8w ago
|
Press Release
| $1.24 $0.9900 | ▲ +20.16% | ▲ +21.07% | $0.7130 (+42.50%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $1.27 $1.27 | · 0.00% | ▲ +0.98% | $0.7130 (−43.86%) |
|
Mar 5, 2026
14w ago
|
8-K
| $1.21 $1.22 | ▲ +0.83% | ▲ +2.35% | $0.7130 (−41.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access